Suntrust Banks Inc. lowered its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,496 shares of the company’s stock after selling 81 shares during the period. Suntrust Banks Inc.’s holdings in ICU Medical were worth $314,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of ICUI. Tower Research Capital LLC TRC bought a new stake in ICU Medical during the second quarter valued at approximately $124,000. Amalgamated Bank acquired a new stake in shares of ICU Medical during the second quarter valued at approximately $214,000. Violich Capital Management Inc. acquired a new stake in shares of ICU Medical during the third quarter valued at approximately $214,000. Teacher Retirement System of Texas raised its stake in shares of ICU Medical by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 2,003 shares of the company’s stock valued at $226,000 after buying an additional 243 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of ICU Medical by 3.0% in the second quarter. ProShare Advisors LLC now owns 2,124 shares of the company’s stock valued at $239,000 after buying an additional 62 shares during the last quarter. 87.80% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ICU Medical, Inc. (NASDAQ:ICUI) traded up 1.07% during mid-day trading on Friday, reaching $136.60. The company’s stock had a trading volume of 61,241 shares. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of 39.39 and a beta of 0.34. ICU Medical, Inc. has a 1-year low of $85.56 and a 1-year high of $154.80. The company’s 50 day moving average price is $141.97 and its 200-day moving average price is $134.04.
ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, November 9th. The company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.18. The firm earned $97.11 million during the quarter, compared to analysts’ expectations of $93.04 million. ICU Medical had a return on equity of 10.70% and a net margin of 15.18%. The business’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 EPS. Analysts predict that ICU Medical, Inc. will post $4.84 earnings per share for the current fiscal year.
Separately, Zacks Investment Research raised ICU Medical from a “hold” rating to a “buy” rating and set a $163.00 price objective on the stock in a report on Monday, January 2nd.
In related news, Director Robert S. Swinney sold 2,025 shares of the company’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $142.88, for a total value of $289,332.00. Following the completion of the sale, the director now directly owns 16,850 shares of the company’s stock, valued at approximately $2,407,528. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 15.90% of the stock is owned by corporate insiders.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).